Journal profile · Ophthalmology
Progress in Retinal and Eye Research
ISSN 1350-9462 · eISSN 1873-1635 · Elsevier Ltd · ENGLAND · Bimonthly · Founded 1994
Progress in Retinal and Eye Research: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 15.5; hybrid open access; APC about USD 6,710; median 117 days to acceptance (102 articles, last 24 months); community-reported acceptance: fairly hard; 70 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Progress in Retinal and Eye Research is published by Elsevier Ltd and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Retinal Development and Disorders, Retinal Diseases and Treatments and Glaucoma and retinal disorders, together about 42.3% of its articles. Its main subfields are Radiology, Nuclear Medicine and Imaging. (generated from OpenAlex topic counts and CAS ranking data)
Progress in Retinal and Eye Research is a Reviews-only journal. By invitation, leading experts write on basic and clinical aspects of the eye in a style appealing to molecular biologists, neuroscientists and physiologists, as well as to vision researchers and ophthalmologists.The journal covers all aspects of eye research, including topics pertaining to the retina and pigment epithelial layer, cornea, tears, lacrimal glands, aqueous humour, iris, ciliary body, trabeculum, lens, vitreous humour and diseases such as dry-eye, inflammation, keratoconus, corneal dystrophy, glaucoma and cataract.Any queries with proposals for Review Articles can be sent directly to Alan Stitt, Editor in Chief.
From the journal's Aims & Scope
Research area (LetPub): Ophthalmology
Editor-in-chief Alan StittPublisher website
Editorial board by country: 5 in mainland China (about 11%); most named United States 14, Australia 6, Mainland China 5, United Kingdom 3, Japan 2 (45 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Retinal Development and DisordersBiochemistry, Genetics and Molecular Biology17%
- Retinal Diseases and TreatmentsMedicine15.2%
- Glaucoma and retinal disordersMedicine10.2%
- Retinal Imaging and AnalysisMedicine5.8%
- Corneal surgery and disordersMedicine4.7%
- Ocular Surface and Contact LensMedicine4.6%
- Corneal Surgery and TreatmentsMedicine4.6%
- Photoreceptor and optogenetics researchNeuroscience4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Ophthalmology | Zone 1 |
Top journal: yesReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Ophthalmology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Ophthalmology | Zone 1 |
Top journal: yesReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 15.5LetPub ·
- Impact factor (publisher)
- 16.2Publisher website ·
- CiteScore 2026-06
- 29.9LetPub ·
- CiteScore (publisher)
- 29.9Publisher website ·
- SJR 2026-06
- 5.18LetPub ·
- SNIP 2026-06
- 6.03LetPub ·
- h-index
- 131LetPub ·
- h-index
- 236OpenAlex ·
- i10-index
- 1,030OpenAlex ·
- 2-year mean citedness
- 12.86OpenAlex ·
- Self-citation rate
- 3.7%LetPub ·
- Share of gold OA articles
- 42.24%LetPub ·
Volume
- Articles per year
- 62LetPub ·
Articles by year OpenAlex count · 1,299 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 68 | 41 | 72 |
| 2025 | 70 | 47 | 745 |
| 2024 | 54 | 45 | 1,652 |
| 2023 | 37 | 22 | 1,510 |
| 2022 | 55 | 37 | 3,339 |
| 2021 | 62 | 37 | 5,413 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
117 daysMedian, submission to acceptance · P25–P75 76 days – 151 days
- Acceptance to online
- median 2 days (102 articles)
- Submission to online
- median 119 days
- Sample
- 102 articles with submission and acceptance dates (149 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average acceptance (community reports)
- Fairly hardLetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- First decision after review
- 45 daysPublisher website ·
- Submission to acceptance
- 127 daysPublisher website ·
- Acceptance to publication
- 3 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 6,710 / EUR 6,280 / GBP 5,370 / JPY 832,240 | — | — | |
| Publisher website | USD 6,670 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websiteWhat to prepare4 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Reference style
- Vancouver
- Highlights
- Optional
Article types accepted3
- perspectiveProgress in Retinal and Eye Research only welcomes Review articles. Articles are generally by invitation and written by leading experts with an appeal not only …Length not stated
- review articleProgress in Retinal and Eye Research only welcomes Review articles. Articles are generally by invitation and written by leading experts with an appeal not only …Length not stated
- review articlesProgress in Retinal and Eye Research only welcomes Review articles.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Authorship
By adhering to the authorship requirements stated above, authors meet the International Committee of Medical Journal Editors (ICMJE) criteria [updated version January 2024] on authorship.
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Double anonymized peer review Model summary
This journal follows a double anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier Ltd
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1994
- ISSN
- 1350-9462
- Electronic ISSN
- 1873-1635
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Progress in Retinal and Eye Research
What CAS zone is Progress in Retinal and Eye Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Progress in Retinal and Eye Research is in Zone 1 of Medicine, and in Zone 1 of the minor category Ophthalmology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Progress in Retinal and Eye Research?
The latest impact factor listed by LetPub is 15.5; CiteScore 29.9, h-index 236.
How long does peer review take at Progress in Retinal and Eye Research?
Based on the dates recorded on 102 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 117 days (interquartile range 76–151 days); the community-reported acceptance is “Fairly hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Progress in Retinal and Eye Research?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Reference style: Vancouver; Highlights: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Progress in Retinal and Eye Research based?
Of the 45 board members whose country the journal's board page names, 5 (about 11%) are in mainland China; the countries named most often are United States (14), Australia (6) and Mainland China (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Progress in Retinal and Eye Research?
According to LetPub and DOAJ records, Progress in Retinal and Eye Research is indexed in SCIE and Scopus.
Is Progress in Retinal and Eye Research open access, and what is the APC?
Progress in Retinal and Eye Research is a hybrid journal. For open-access publication: APC about USD 6,710.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .